These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12005246)

  • 1. Effects of candesartan and perindopril on renal function, TGF-beta1 plasma levels and excretion of prostaglandins in stable renal allograft recipients.
    Hetzel GR; Hermsen D; Hohlfeld T; Rettich A; Ozcan F; Fusshöller A; Grabensee B; Plum J
    Clin Nephrol; 2002 Apr; 57(4):296-302. PubMed ID: 12005246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
    Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
    Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of candesartan on glomerular hemodynamics and permselectivity in patients with favorable renal allograft function.
    Hetzel GR; Plum J; Fusshöller A; Voiculescu A; Grünberg W; Grabensee B
    Transplantation; 2005 Mar; 79(6):710-5. PubMed ID: 15785378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
    Sato A; Tabata M; Hayashi K; Saruta T
    Clin Exp Nephrol; 2003 Sep; 7(3):215-20. PubMed ID: 14586718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
    Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ
    Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renin-angiotensin system blockade safely reduces blood pressure in patients with minor ischemic stroke during the acute phase.
    Nakamura T; Tsutsumi Y; Shimizu Y; Uchiyama S
    J Stroke Cerebrovasc Dis; 2010; 19(6):435-40. PubMed ID: 20702114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transforming growth factor beta1 and additional renoprotective effect of combination ACE inhibitor and angiotensin II receptor blocker in hypertensive subjects with minor renal abnormalities: a 24-week randomized controlled trial.
    Scaglione R; Argano C; Corrao S; Di Chiara T; Licata A; Licata G
    J Hypertens; 2005 Mar; 23(3):657-64. PubMed ID: 15716710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition.
    Berger ED; Bader BD; Ebert C; Risler T; Erley CM
    J Hypertens; 2002 Apr; 20(4):739-43. PubMed ID: 11910311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients.
    Suwelack B; Kobelt V; Erfmann M; Hausberg M; Gerhardt U; Rahn KH; Hohage H
    Transpl Int; 2003 May; 16(5):313-20. PubMed ID: 12759722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.
    Rossing K; Jacobsen P; Pietraszek L; Parving HH
    Diabetes Care; 2003 Aug; 26(8):2268-74. PubMed ID: 12882847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy.
    Campistol JM; Iñigo P; Jimenez W; Lario S; Clesca PH; Oppenheimer F; Rivera F
    Kidney Int; 1999 Aug; 56(2):714-9. PubMed ID: 10432413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin-converting enzyme inhibition in adult hypertensive rats: a stereological study of renal filtration surface area.
    Dunstan HJ; Briscoe TA; Bertram JF; Johnston CI; Black MJ
    Clin Exp Pharmacol Physiol; 2003; 30(1-2):72-6. PubMed ID: 12542457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria.
    Kincaid-Smith P; Fairley K; Packham D
    Nephrol Dial Transplant; 2002 Apr; 17(4):597-601. PubMed ID: 11917051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Divergent effects of calcium channel and angiotensin converting enzyme blockade on glomerulotubular function in cyclosporine-treated renal allograft recipients.
    Sennesael JJ; Lamote JG; Violet I; Tasse S; Verbeelen DL
    Am J Kidney Dis; 1996 May; 27(5):701-8. PubMed ID: 8629631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis.
    Nakamura T; Obata J; Kimura H; Ohno S; Yoshida Y; Kawachi H; Shimizu F
    Kidney Int; 1999 Mar; 55(3):877-89. PubMed ID: 10027924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of administering the maximal dose of candesartan in renal transplant recipients.
    Okumi M; Kawada N; Ichimaru N; Kitamura H; Abe T; Imamura R; Kojima Y; Kokado Y; Isaka Y; Rakugi H; Nonomura N; Moriyama T; Takahara S
    Clin Exp Nephrol; 2011 Dec; 15(6):907-15. PubMed ID: 21818547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary transforming growth factor-beta1 excretion in renal allograft recipients during the early post-transplantation period.
    Goumenos DS; Tsakas S; Karavias D; Savidaki I; Karatzas T; Vlachojannis JG
    Ren Fail; 2003 Jul; 25(4):561-8. PubMed ID: 12911160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ACE inhibitors attenuate expression of renal transforming growth factor-beta1 in humans.
    Shin GT; Kim SJ; Ma KA; Kim HS; Kim D
    Am J Kidney Dis; 2000 Nov; 36(5):894-902. PubMed ID: 11054345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.